A complete protein truncation test for BRCA1 and BRCA2

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• The protein truncation test (PTT) is a rapid method for identifying novel mutations in tumor suppressor genes.
• BRCA1/2 genes are crucial tumor suppressors, and mutations are common in hereditary cancers.
• PTT allows screening of large coding sequences efficiently using PCR and in vitro transcription/translation.

Purpose of the Study:

• To evaluate the effectiveness of PTT for screening BRCA1/2 mutations.
• To identify factors influencing the false negative rate of PTT.
• To propose optimization strategies for improving PTT accuracy in mutation detection.

Main Methods:

• Screening of the 16 kb BRCA1/2 coding sequence using nine overlapping segments.
• Utilizing coupled in vitro transcription/translation and SDS-PAGE for protein product analysis.
• Investigating the impact of segment design, gel parameters, and nonsense-mediated mRNA decay (NMD).

Main Results:

• PTT can screen large coding sequences, with BRCA1/2 requiring nine segments.
• Theoretical false negative rate for BRCA1/2 mutations is 10%, but practical rates are higher, especially with cDNA.
• Factors like segment design, gel conditions, and NMD significantly affect PTT accuracy.

Conclusions:

• PTT is a valuable tool for detecting mutations in tumor suppressor genes, including BRCA1/2.
• Optimization of PTT parameters is essential to minimize false negatives.
• Inhibiting NMD, for example, with cycloheximide, can enhance PTT effectiveness.